The role of routine follow-up after gynecological malignancy

2005 ◽  
Vol 15 (3) ◽  
pp. 413-419 ◽  
Author(s):  
F. M. Kew ◽  
A. P. Roberts ◽  
D. J. Cruickshank
Keyword(s):  
Cervical Cancer ◽  
Endometrial Cancer ◽  
Poster Presentation ◽  
Survival Benefit ◽  
Gynecological Cancer ◽  
Case Series ◽  
Gynecological Malignancy ◽  
Vulval Cancer ◽  
Prospective Research

The objective of this article was to determine the evidence base for routine follow-up after gynecological malignancy. Only articles with a survival analysis were included. Relevant articles were identified by a comprehensive literature search of the main biomedical databases, hand searching of references of selected articles, and expert spotting of relevant journals and proceedings of international meetings. A two-stage extraction of data was undertaken. No prospective trials were identified. Twenty-nine retrospective case series analyses and one poster presentation met the inclusion criteria. Eight articles and one letter on endometrial cancer, six articles and one poster presentation on cervical cancer, and two articles in vulval cancer were reviewed. Only one article in endometrial cancer showed any survival benefit from routine follow-up, but it was of very poor methodologic quality. Two articles found a survival benefit from routine follow-up after cervical cancer. The two articles on vulval cancer did not find any survival benefit from routine review. There is no prospective research on the benefits of routine follow-up after gynecological cancer. Retrospective evidence calls in to question the benefit of universal follow-up. Prospective research is urgently needed.

scholarly journals Postoperative survival and functional outcomes for patients with metastatic gynecological cancer to the spine: case series and review of the literature

2016 ◽  
Vol 24 (1) ◽  
pp. 131-144 ◽  
Author(s):  
Ann Liu ◽  
Eric W. Sankey ◽  
C. Rory Goodwin ◽  
Thomas A. Kosztowski ◽  
Benjamin D. Elder ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Endometrial Cancer ◽  
Median Survival ◽  
Functional Outcomes ◽  
Gynecological Cancer ◽  
Spinal Metastases ◽  
Postoperative Survival ◽  
Review Of The Literature ◽  
Gynecological Cancers

OBJECT Spinal metastases from gynecological cancers are rare, with few cases reported in the literature. In this study, the authors examine a series of patients with spinal metastases from gynecological cancer and review the literature. METHODS The cases of 6 consecutive patients who underwent spine surgery for metastatic gynecological cancer between 2007 and 2012 at a single institution were retrospectively reviewed. The recorded demographic, operative, and postoperative factors were reviewed, and the functional outcomes were determined by change in Karnofsky Performance Scale and the American Spine Injury Association (ASIA) score during follow-up. A systematic review of the literature was also performed to evaluate outcomes for patients with similar gynecological metastases to the spine. RESULTS In this series, details regarding metastatic gynecological cancers to the spine are as follows: 2 patients with cervical cancer (both presented at age 46 years, mean postoperative survival of 32 months), 2 patients with endometrial cancer (mean age of 40 years, mean postoperative survival of 26 months), and 2 patients with leiomyosarcoma (mean age of 44 years, mean postoperative survival of 20 months). All patients presented with pain, and no complications were noted following surgery. All patients with known follow-up had stable or improved neurological outcomes, performance status, and improved pain, without local recurrence of tumor. Overall median survival after diagnosis of metastatic spine lesions for all cases in the literature as well as those treated by the authors was 15 months. When categorized by type, median survival of patients with cervical cancer (n = 2), endometrial cancer (n = 26), and leiomyosarcoma (n = 16) was 32, 10, and 22.5 months, respectively. CONCLUSIONS Gynecological cancers metastasizing to the spine are rare. In this series, overall survival following diagnosis of spinal metastasis and surgery was 27 months, with cervical cancer, endometrial cancer, and leiomyosarcoma survival being 32, 26, and 20 months, respectively. Combined with literature cases, survival differs depending on primary histology, with decreasing survival from cervical cancer (32 months) to leiomyosarcoma (22.5 months) to endometrial cancer (10 months). Integrating such information with other patient factors may more accurately guide decision making regarding management of such spinal lesions.

Mismatch Repair Genes and Microsatellite Instability as Molecular Markers for Gynecological Cancer Detection

2002 ◽  
Vol 227 (8) ◽  
pp. 579-586 ◽  
Author(s):  
Roman Miturski ◽  
Michał Bogusiewicz ◽  
Carmella Ciotta ◽  
Margherita Bignami ◽  
Marek Gogacz ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Mismatch Repair ◽  
Cancer Detection ◽  
Xeroderma Pigmentosum ◽  
Gynecological Cancer ◽  
Epidemiological Studies ◽  
Mismatch Repair Genes ◽  
The Past ◽  
Repair Genes

Due to major developments in genetics over the past decade, molecular biology tests are serving promising tools in early diagnosis and follow-up of cancer patients. Recent epidemiological studies revealed that the risk for each individual to develop cancer is closely linked to his/her own genetic potentialities. Some populations that are defective in DNA repair processes, for example in Xeroderma pigmentosum or in the Lynch syndrome, are particularly prone to cancer due to the accumulation of mutations within the genome. Such populations would benefit from the development of tests aimed at identifying people who are particularly at risk. Here, we review some data suggesting that the inactivation of mismatch repair is often found in endometrial cancer and we discuss molecular-based strategies that would help to identify the affected individuals in families with cases of glandular malignancies.

scholarly journals Serum carcinoembryonic antigen as a tumour marker in patients with endometrial cancer

2016 ◽  
Vol 23 (5) ◽  
pp. 439 ◽  
Author(s):  
Y. Hashiguchi ◽  
M. Kasai ◽  
T. Fukuda ◽  
T. Ichimura ◽  
T. Yasui ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Carcinoembryonic Antigen ◽  
Menopausal Status ◽  
Elevated Serum ◽  
Case Series ◽  
Myometrial Invasion ◽  
Tumour Markers ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea

Background No potential tumour markers have been validated for prognosis in endometrial cancer. However, carcinoembryonic antigen (cea) is one of the most widely used tumour markers in various types of cancer. Although cea expression in endometrial cancer has been investigated, its prognostic value remains controversial, and no studies have investigated serum cea levels in large case series. In the present study, we investigated diagnostic and prognostic applications of serum cea for endometrial cancer.Methods This prospective study was approved by our Institutional Review Board. Between January 2006 and December 2012, serum cea was measured prospectively in 215 patients with endometrial cancer and was subsequently measured during treatment and at scheduled follow-up examinations in patients with elevated basely ne serum cea.Results During the study period, 215 patients (142 stage i, 19 stage ii, 32 stage iii, 22 stage iv) were treated for endometrial cancer. By the time of last follow-up, 52 had relapsed (24.2%), and the median follow-up duration was 45 months (range: 1–95 months). Elevated serum cea was identified in 25 patients (11.6%) and was associated with histologic type (p = 0.04), histologic grade (p = 0.03), and myometrial invasion depth (p = 0.01). Elevated serum cea was not related to clinical stage, lymph node metastasis, distant metastasis, age, menopausal status, or body mass index. Relapse of disease was related to elevated serum cea (p = 0.006).Conclusions Serum cea is a potential prognostic indicator for endometrial cancer.

scholarly journals Cytopathologic follow-up of women with cervical cancer post-radiotherapy: case series

2018 ◽  
Vol 54 (2) ◽  
Author(s):  
Ruan Carlos G. Silva ◽  
Rachel Di Paola V. Figueirêdo ◽  
Amanda Cristina O. Silva ◽  
Carlos Eduardo Q. Lima ◽  
Sibele R. Oliveira ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Case Series

scholarly journals METASTATIC CERVICAL CANCER TREATED WITH PACLITAXEL, IFOSFAMIDE AND CISPLATIN (TIP), FOLLOWED BY LOCAL TREATMENT AND LONG-TERM FOLLOW UP: CASE SERIES

2019 ◽  
Author(s):  
Graziela Zibetti Dal Molin ◽  
Milena Martello Cristófalo ◽  
Larissa Gomes ◽  
Celso Luis Borrelli ◽  
José Carlos Sadalla ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Local Treatment ◽  
Case Series ◽  
Long Term Follow Up

scholarly journals Human papillomavirus genotypes in cervical cancers in Mozambique

2004 ◽  
Vol 85 (8) ◽  
pp. 2189-2190 ◽  
Author(s):  
Pontus Naucler ◽  
Flora Mabota da Costa ◽  
Otto Ljungberg ◽  
Antonio Bugalho ◽  
Joakim Dillner
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Case Series ◽  
Cervical Neoplasia ◽  
Consecutive Case ◽  
Substantial Impact ◽  
Cervical Cancers ◽  
Hpv Types ◽  
Oncogenic Hpv

The distribution of human papillomavirus (HPV) types in cervical cancers is essential for design and evaluation of HPV type-specific vaccines. To follow up on a previous report that HPV types 35 and 58 were the dominant HPV types in cervical neoplasia in Mozambique, the HPV types in a consecutive case series of 74 invasive cervical cancers in Mozambique were determined. The most common worldwide major oncogenic HPV types 16 and 18 were present in 69 % of cervical cancers, suggesting that a vaccine targeting HPV-16 and -18 would have a substantial impact on cervical cancer also in Mozambique.

scholarly journals Malignant Tumors of the Female Genital Tract – a Hospital Based Analysis

2016 ◽  
Vol 10 (2) ◽  
pp. 24-28
Author(s):  
R Joshi ◽  
G Baral ◽  
K Malla
Keyword(s):  
Ovarian Cancer ◽  
Cervical Cancer ◽  
Endometrial Cancer ◽  
Genital Tract ◽  
Malignant Tumors ◽  
Female Genital Tract ◽  
Limited Data ◽  
Corpus Uteri ◽  
Female Genital

Aims: The incidence of cancer and the cancer related deaths are increasing worldwide. There is limited data regarding  gynecological cancers in Nepal. This study is conducted to analyze the trends of female genital tract malignancies in Paropakar Maternity and Women’s Hospital (PMWH) and compare it with the national/international data.Methods: This was a retrospective study conducted in Department of Obstetrics/Gynecology and Pathology in PMWH.  All female diagnosed with the genital tract malignancies from July 2013 to July 2015 were included in the study.Results: Among 62 cases, cervical cancer was the commonest (71%) followed by ovarian cancer (14%), endometrial cancer (8%) and choriocarcinoma (3%). Majority of women belonged to 50-59 years for each type of tumors. Four-fifth of endometrial, half of the cervical and one-third of ovarian cancers were among grand-multipara. Sixty nine percent of women received treatment with 22 (9 cervical, 9 ovarian, 3 endometrial and one of corpus uteri)  surgical and 21 primary chemo/radiotherapy but 19 (31%) were lost for follow-up. Squamous type of cervical cancer was the commonest (93%).Conclusions: Cervical cancer was the commonest genital tract malignancy followed by ovarian cancer, endometrial cancer and choriocarcinoma. For each type of tumors, 50-59 years was the common age group and grand multiparity was seen in half of the women with the cervical cancer. Squamous type of cervical cancer was the commonest variety.  

Locally Advanced Cervical Cancer in Pregnancy: Overcoming the Challenge. A Case Series and Review of the Literature

2016 ◽  
Vol 26 (8) ◽  
pp. 1490-1496 ◽  
Author(s):  
Caterina Ricci ◽  
Giovanni Scambia ◽  
Rosa De Vincenzo
Keyword(s):  
Cervical Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Gynecological Cancer ◽  
Invasive Cervical Cancer ◽  
Locally Advanced ◽  
Case Series ◽  
Complex Situation ◽  
Response To Chemotherapy ◽  
Cancer In Pregnancy ◽  
In Pregnancy

ObjectiveCervical cancer is the most common gynecological cancer occurring in pregnancy, creating a complex situation both for patient and physician. Neoadjuvant chemotherapy is an innovative way of managing cervical cancer in pregnancy.MethodsIn our paper, we report a retrospective case series of 4 women treated with chemotherapy for invasive cervical cancer during pregnancy in our center over the last 5 years, and we summarize the available literature and guidelines.ResultsAll the cases were locally advanced cervical cancers that received chemotherapy with platinum and/or taxanes. All patients showed a good response to chemotherapy and a radical surgery was performed with no additional morbidities at the cesarean delivery time in 3 of 4 cases. Three of 4 patients are alive and have a good outcome with no recurrence of disease up to date. One patient died because of recurrent disease 2 years after the first-line treatment during pregnancy. All babies are alive and well up to date (maximum follow-up, 63 months).ConclusionsEven if there are no standardized practices in the treatment of cervical cancer in pregnancy, in our opinion, neoadjuvant chemotherapy can be a very useful strategy for patients and physicians facing the challenge.

scholarly journals Menopause and Gynecological Malignancy

2013 ◽  
Vol 1 (2) ◽  
pp. 75-79 ◽  
Author(s):  
Jannatul Ferdous ◽  
Sabera Khatun
Keyword(s):  
Ovarian Cancer ◽  
Cervical Cancer ◽  
Postmenopausal Women ◽  
Gynecological Cancer ◽  
Gynecologic Cancer ◽  
False Negative ◽  
Ca 125 ◽  
Biological Aging ◽  
Premature Menopause ◽  
Gynecological Malignancy

ABSTRACT Menopause is a consequence of biological aging. Menopause does not cause cancer, but the risk of developing cancer increase as a woman ages. Treatment of cancer can also cause premature menopause. Among the gynecological cancer, cervical cancer tops the list of common cancer. Postmenopausal women are prone to have persistent human papillomavirus (HPV) infection. There is no role of primary prevention of cervical cancer by vaccination in postmenopausal women. Secondary prevention by Paps smear only may provide false negative result as the cervix is often flushed with the vagina. So, scraping by Ayres spatula and using endometrial brush is necessary in these women. Unfortunately, symptoms of cervical cancer in postmenopausal women are nonspecific and associated with comorbidities. So, any symptom of cervical cancer in postmenopausal women should be properly evaluated. Ovarian cancer is the number one cancer of death among all gynecologic malignancies. Majority of the ovarian cancer in postmenopausal women present with vague symptom and have the advance stage at prevention. Currently, no reliable screening test is available. Yearly routine pelvic examination, transvaginal ultrasonography and serum CA-125 can be performed in selective high-risk women only. Endometrial cancer is the most common gynecologic cancer in the USA. Most endometrial carcinomas are diagnosed at an early stage and have a good prognosis. Though vulvar and vaginal cancer are rare malignancies, yet these are prevalent in postmenopausal women. Any postmenopausal women with long-term intense itching, pervaginal discharge or any ulcer of vulva or vagina should be evaluated properly. How to cite this article Khatun S, Ferdous J. Menopause and Gynecological Malignancy. J South Asian Feder Menopause Soc 2013;1(2):75-79.

scholarly journals Radiomics in cervical and endometrial cancer

2021 ◽  
pp. 20201314
Author(s):  
Lucia Manganaro ◽  
Gabriele Maria Nicolino ◽  
Miriam Dolciami ◽  
Federica Martorana ◽  
Anastasios Stathis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cervical Cancer ◽  
Developing Countries ◽  
Endometrial Cancer ◽  
Prognostic Factors ◽  
Clinical Decision ◽  
Quantitative Information ◽  
Response To Therapy ◽  
Gynecological Malignancy

Radiomics is an emerging field of research that aims to find associations between quantitative information extracted from imaging examinations and clinical data to support the best clinical decision. In the last few years, some papers have been evaluating the role of radiomics in gynecological malignancies, mainly focusing on ovarian cancer. Nonetheless, cervical cancer is the most frequent gynecological malignancy in developing countries and endometrial cancer is the most common in western countries. The purpose of this narrative review is to give an overview of the latest published papers evaluating the role of radiomics in cervical and endometrial cancer, mostly evaluating association with tumor prognostic factors, with response to therapy and with prediction of recurrence and distant metastasis.

Sign in / Sign up

Export Citation Format

Share Document